Benchmark Research Announces New Shreveport Site
Benchmark Research has announced a new site located in Shreveport, Louisiana will bring the company to 9 sites total across the states of Texas, California, and Louisiana. This clinic will be Benchmark’s first to focus on In-patient and out-patient psychiatric studies as well as groundbreaking studies with Cannabis and Psychedelics such as LSD, Psilocybin, Ketamine, MDMA, and others.
Benchmark Shreveport (SHV) will be spearheaded by Brian Wooten, the prior owner of the clinic. Brian is a CCRC with a master’s degree in clinical psychology. In the past 27 years throughout his career, he has held various positions in psychiatric medicine management including 25 years in various roles in psychiatric clinical research from CRC to site owner.
Read more about the new clinic here.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
